Shenzhen Hepalink Pharmaceutical Group (09989): ENOXAPARIN approved in Argentina.

Shenzhen Hepalink Pharmaceutical Group (09989) announced that Enoparin (one of the leading drugs in the group's enoxaparin sodium injection) produced by its wholly-owned subsidiary Shenzhen Tian Dao Pharmaceutical Co., Ltd. has been approved for sale by the Argentine National Administration of Drugs, Food and Medical Technology (ANMAT). This approval means that the enoxaparin sodium preparation of the Shenzhen Hepalink Pharmaceutical Group will be sold in the Argentine market, further increasing the group's market share globally. The company believes that this approval is another important achievement in the internationalization of the group's formulation business, once again demonstrating the group's ability to enter overseas markets. In the future, the group will continue to exert efforts to accelerate the expansion of global markets and sales channels, laying the groundwork for further strengthening the development of overseas markets.